title: Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.
abstract: We conducted a retrospective analysis to investigate the clinical outcome of combined-modality therapy using multiagent chemotherapy and involved-field radiotherapy in treatment of children with Hodgkin's lymphoma. Fifty eight cases with newly diagnosed Hodgkin's lymphoma were analyzed. The median follow-up duration was 46 months (range 3-72 months). The 4-year overall and event-free survival rates were 91.5% and 69.7% respectively. High-risk disease (stage IIIB and IV), presence of B symptoms, lymphocyte depletion subtype, bulky disease and late response to chemotherapy were poor prognostic factors. Stage-adapted combined-modality therapy resulted in satisfactory outcome in treatment of pediatric Hodgkin's lymphoma.
authors.affiliation: Department of Pediatric Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
authors.forename: Amany
authors.initials: A
authors.lastname: Ali
authors.forename: Heba
authors.initials: H
authors.lastname: Sayed
authors.forename: Ahmed
authors.initials: A
authors.lastname: Farrag
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Sayed
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D018570:Risk Assessment